Get the Stockscreener App
33.43
0.96%
-0.48
Lenz Therapeutics Inc stock is traded at $33.43, with a volume of 23,739.
It is down -0.96% in the last 24 hours and up +23.52% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$33.91
Open:
$34
24h Volume:
23,739
Relative Volume:
0.15
Market Cap:
$932.56M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-73.92M
1W Performance:
-1.02%
1M Performance:
+23.52%
6M Performance:
+80.18%
1Y Performance:
+0.00%
1-Day Range:
$33.10
$34.40
1-Week Range:
$31.59
$35.40
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LENZ | 33.89 | 932.56M | 0 | -69.47M | -73.92M | 0.00 |
| VRTX | 448.30 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.33 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.38 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.62 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat
TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan
Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance
FY2024 EPS Estimate for LENZ Therapeutics Boosted by Analyst - MarketBeat
William Blair Has Bullish Outlook for LENZ FY2024 Earnings - MarketBeat
Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks
LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com UK
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider.com
LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer - The Manila Times
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times
LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St
Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter
LENZ reports positive Chinese study data for far-sightedness drug - MSN
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL
Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
One new option listing and ten option delistings on October 21st - TipRanks
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com
Behind the Bell: LENZ Therapeutics - Nasdaq
FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance
Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance
TJX Companies (TJX-N) QuotePress Release - The Globe and Mail
Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World
Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):